122 related articles for article (PubMed ID: 25151406)
1. Is the differentiation into molecular subtypes of breast cancer important for staging, local and systemic therapy, and follow up?
Sonnenblick A; Fumagalli D; Sotiriou C; Piccart M
Cancer Treat Rev; 2014 Oct; 40(9):1089-95. PubMed ID: 25151406
[TBL] [Abstract][Full Text] [Related]
2. [Clinical features and prognosis analysis of different breast cancer molecular subtypes].
Yang Q; Chen J; Li HJ; Yu M; Tian CX; Lü Q
Zhonghua Zhong Liu Za Zhi; 2011 Jan; 33(1):42-6. PubMed ID: 21575463
[TBL] [Abstract][Full Text] [Related]
3. Patients with anti-HER2 responsive disease: definition and adjuvant therapies.
Burstein HJ
Breast; 2011 Oct; 20 Suppl 3():S132-4. PubMed ID: 22015280
[TBL] [Abstract][Full Text] [Related]
4. Partial breast irradiation: targeting volume or breast molecular subtypes?
Orecchia R; Leonardi MC
Breast; 2013 Aug; 22 Suppl 2():S137-40. PubMed ID: 24074774
[TBL] [Abstract][Full Text] [Related]
5. A novel morphologic-molecular recurrence predictive model refines traditional prognostic tools for invasive breast carcinoma.
Ni YB; Tsang JY; Chan SK; Tse GM
Ann Surg Oncol; 2014 Sep; 21(9):2928-33. PubMed ID: 24743910
[TBL] [Abstract][Full Text] [Related]
6. Is there a case for anti-HER2 therapy without chemotherapy in early breast cancer?
Constantinidou A; Smith I
Breast; 2011 Oct; 20 Suppl 3():S158-61. PubMed ID: 22015286
[TBL] [Abstract][Full Text] [Related]
7. Importance of confirming HER2 overexpression of recurrence lesion in breast cancer patients.
Nakamura R; Yamamoto N; Onai Y; Watanabe Y; Kawana H; Miyazaki M
Breast Cancer; 2013 Oct; 20(4):336-41. PubMed ID: 22367960
[TBL] [Abstract][Full Text] [Related]
8. Survival and clinicopathological characteristics of breast cancer patient according to different tumour subtypes as determined by hormone receptor and Her2 immunohistochemistry. a single institution survey spanning 1998 to 2010.
García Fernández A; Giménez N; Fraile M; González S; Chabrera C; Torras M; González C; Salas A; Barco I; Cirera L; Cambra MJ; Veloso E; Pessarrodona A
Breast; 2012 Jun; 21(3):366-73. PubMed ID: 22487206
[TBL] [Abstract][Full Text] [Related]
9. [Clinical characteristics and prognosis of different subtypes of breast cancer].
Yuan ZY; Wang SS; Zhu MQ; Zheng L; Luo WB; Zhou ZM; Guan ZZ
Zhonghua Zhong Liu Za Zhi; 2008 Jun; 30(6):456-61. PubMed ID: 19024523
[TBL] [Abstract][Full Text] [Related]
10. Triple-negative breast cancers: unique clinical presentations and outcomes.
Billar JA; Dueck AC; Stucky CC; Gray RJ; Wasif N; Northfelt DW; McCullough AE; Pockaj BA
Ann Surg Oncol; 2010 Oct; 17 Suppl 3():384-90. PubMed ID: 20853062
[TBL] [Abstract][Full Text] [Related]
11. Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors.
Brouckaert O; Pintens S; Van Belle V; Van Huffel S; Camerlynck E; Amant F; Leunen K; Smeets A; Berteloot P; Van Limbergen E; Decock J; Hendrickx W; Weltens C; Van den Bogaert W; Vanden Bempt I; Drijkoningen M; Paridaens R; Wildiers H; Vergote I; Christiaens MR; Neven P
Breast Cancer Res Treat; 2009 May; 115(2):349-58. PubMed ID: 18629635
[TBL] [Abstract][Full Text] [Related]
12. Low protein expression of MET in ER-positive and HER2-positive breast cancer.
Zagouri F; Brandstetter A; Moussiolis D; Chrysikos D; Dimitrakakis C; Tsigginou A; Marinopoulos S; Zografos GC; Sergentanis TN; Dimopoulos MA; Filipits M
Anticancer Res; 2014 Mar; 34(3):1227-31. PubMed ID: 24596364
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer.
Munzone E; Botteri E; Sandri MT; Esposito A; Adamoli L; Zorzino L; Sciandivasci A; Cassatella MC; Rotmensz N; Aurilio G; Curigliano G; Goldhirsch A; Nolè F
Clin Breast Cancer; 2012 Oct; 12(5):340-6. PubMed ID: 23040002
[TBL] [Abstract][Full Text] [Related]
14. Apoptosis-, proliferation, immune function-, and drug resistance- related genes in ER positive, HER2 positive and triple negative breast cancer.
Kolacinska A; Chalubinska J; Zawlik I; Szymanska B; Borowska-Garganisz E; Nowik M; Fendler W; Kubiak R; Pawlowska Z; Morawiec Z; Szemraj J
Neoplasma; 2012; 59(4):424-32. PubMed ID: 22489698
[TBL] [Abstract][Full Text] [Related]
15. Androgen receptor expression shows distinctive significance in ER positive and negative breast cancers.
Tsang JY; Ni YB; Chan SK; Shao MM; Law BK; Tan PH; Tse GM
Ann Surg Oncol; 2014 Jul; 21(7):2218-28. PubMed ID: 24639191
[TBL] [Abstract][Full Text] [Related]
16. Discordant expression of hormone receptors and HER2 in breast cancer. A retrospective comparison of primary tumors with paired metachronous recurrences or metastases.
Arapantoni-Dadioti P; Valavanis C; Gavressea T; Tzaida O; Trihia H; Lekka I
J BUON; 2012; 17(2):277-83. PubMed ID: 22740206
[TBL] [Abstract][Full Text] [Related]
17. Biological subtypes of breast cancer: current concepts and implications for recurrence patterns.
Cadoo KA; Fornier MN; Morris PG
Q J Nucl Med Mol Imaging; 2013 Dec; 57(4):312-21. PubMed ID: 24322788
[TBL] [Abstract][Full Text] [Related]
18. Multifocal breast cancer documented in large-format histology sections: long-term follow-up results by molecular phenotypes.
Pekar G; Hofmeyer S; Tabár L; Tarján M; Chen TH; Yen AM; Chiu SY; Hellberg D; Gere M; Tot T
Cancer; 2013 Mar; 119(6):1132-9. PubMed ID: 23279980
[TBL] [Abstract][Full Text] [Related]
19. Human epidermal growth factor receptor-2 positivity predicts locoregional recurrence in patients with T1-T2 breast cancer.
Cefaro GA; Genovesi D; Trignani M; DI Nicola M
Anticancer Res; 2014 Mar; 34(3):1207-12. PubMed ID: 24596361
[TBL] [Abstract][Full Text] [Related]
20. Staging of women with breast cancer after introduction of sentinel node guided axillary dissection.
Tvedskov TF
Dan Med J; 2012 Jul; 59(7):B4475. PubMed ID: 22759850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]